The short version of GHRH analog fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-05 and is reviewed periodically as new material appears.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Various types of genital piercings can be inserted in the clitoris area. The clitoris piercing passes through the clitoral glans proper. However, performing this piercing depends heavily on anatomy and only a small percentage of people are anatomically suited for it (i.e., a sufficiently developed glans clitoridis is needed). The term "clit piercing" therefore often refers to the more common clitoral hood piercing. These are usually channeled in the form of vertical piercings, and, to a lesser extent, horizontal piercings. The triangle piercing is a very deep horizontal hood piercing and is done behind the clitoris as opposed to in front of it. For styles such as the Isabella piercing, which passes through the clitoral shaft but is placed deep at the base, they provide unique stimulation and still require the proper genital build. The Isabella starts between the clitoral glans and the urethra, exiting at the top of the clitoral hood; this piercing is highly risky concerning the damage that may occur because of intersecting nerves. (See Clitoral index.)
Following this transfer event, the electron-deficient anion undergoes internal rearrangement and fragments. NETD is the ion/ion analogue of electron-detachment dissociation (EDD). NETD is compatible with fragmenting peptide and proteins along the backbone at the Cα-C bond. The resulting fragments are usually a•- and x-type product ions.
Glycoprotein hormones, alpha polypeptide is a protein that in humans is encoded by the CGA gene. Thyroid-stimulating hormone (TSH) and the gonadotropin hormones human chorionic gonadotropin (hCG), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) are heterodimers consisting of alpha and beta subunits (also called chains) that are associated non-covalently. The alpha subunits of these four human glycoprotein hormones are identical; however, their beta chains are unique and confer biological specificity. The protein encoded by this gene is the alpha subunit and belongs to the glycoprotein hormones alpha chain family. CGA levels are regulated by ELAVL1/HuR, and the small molecule Eltrombopag, which targets HuR/RNA interactions, has been shown to reduce CGA levels in human cultured cells.
Futures studies is the study of social and technological progress. It aims to explore the range of plausible futures and incorporate human values in the development of new technologies. More generally, futures researchers are interested in improving "the freedom and welfare of humankind". It relies on a thorough quantitative and qualitative analysis of past and present technological trends, and attempts to rigorously extrapolate them into the future. Science fiction is often used as a source of ideas. Futures research methodologies include survey research, modeling, statistical analysis, and computer simulations.
=== Annual cultural events === The annual events in Albany include the Northwest Art and Air Festival, River Rhythms, Summer Sounds (formerly Mondays at Monteith), Veteran's Day Parade, Albany Upstairs Downtown Wine Walk and the Craft Brew Smackdown. The once popular Albany Timber Carnival ended in 2000. An attempt to revive the event in 2008 was unsuccessful. The Albany Arts Festival was held from 1970 until the late 1980s.
Sources: en.wikipedia.org
=== Aftermath === Sunny's family remained convinced that her husband had tried to murder her and was upset that Cosima had chosen to take her father's side. As a result, in 1981, Sunny's mother, Annie Laurie Aitken, disinherited Cosima, denying her share of the estate upon Aitken's death on May 4, 1984. In July 1985, ten days after Claus von Bülow was acquitted at his second trial, Ala and Alexander filed a $56 million civil lawsuit against him, on their mother's behalf. On December 24, 1987, this case was settled out of court when Claus von Bülow agreed to divorce her, give up all claims to her fortune, then estimated between $25 million and $40 million, and leave the country. In exchange, Cosima was reinstated in Aitken's will and received $30 million as her one-third share of the estate. After the trials, Ala and Alexander founded the Sunny von Bülow National Victim Advocacy Center in Fort Worth, Texas, now the National Center for Victims of Crime in Washington, DC, and the Sunny von Bülow Coma and Head Trauma Research Foundation in New York.
==== Cytochrome c oxidase ==== There have been several hypotheses about the role of copper and some of its neurological manifestations. Some suggest that disruptions in cytochrome c oxidase, also known as Complex IV, of the electron transport chain, is responsible for spinal cord degeneration.
== Co-Workers == Klaus Mosbach supervised more than sixty Ph.D.’s over the years. A number of highly recognized scientists emerged from this pool, including the following professors C. Borrebaeck (in part), B.Sellergren (who is now a professor in Germany). P. Brodelius, Leif Bulow, B. Danielsson, B. Hahn-Hägerdahl (in part), A.C. Koch. Schmidt, P.O. Larsson, C. F. Mandenius, B. Mattiasson, M.O. Månsson, I.A. Nicholls (starting as post doc), R. Ohlsson (in part), Lei Ye and S. Olsson working all in Sweden. To this a number of Professors working in other countries outside Sweden including, L.Fischer, K. Haupt, C.Lowe, H.Zhang, Deepak Chandrasekaran. Mosbach collaborated with numerous companies over the years, including Biogen and later Hybritech, Eli Lilly, Igen, Hofman la Roche and was involved in the formation of start-up companies by himself likewise former students of him have been successful in starting up companies like B.Ekberg, N.Siegbahn, Kurt Nilsson, Kjell Nilsson, Dariao Kriz.
== References == Books B Gaze and B Smith, Equality and Discrimination Law in Australia: An Introduction (2017) E McGaughey, A Casebook on Labour Law (Hart 2019) J Riley Munton, Labour Law: An Introduction to the Law of Work (OUP 2021) C Ronalds and E Raper, Discrimination Law and Practice (5th edn 2019) A Stewart, A Forsyth, M Irving, R Johnstone, S McCrystal, Creighton & Stewart's Labour Law (6th edn Federation 2016) Articles A Forsyth, 'There's one big reason wages are stagnating: the enterprise bargaining system is broken, and in terminal decline (June 1, 2022) The Conversation P Gahan, 'The Future of State Industrial Regulation: Can We Learn From Victoria?' (2005) Australian Review of Public Affairs D Hyslop and S Stillman, 'Youth minimum wage reform and the labour market' (March 2004) New Zealand Treasury Working Paper 04/03 R Owens, 'Unfinished constitutional business: building a national system to regulate work' (2009) 22 AJLL 258 E Schofield-Georgeson and J Riley Munton, 'Precarious work in the high court' (2023) 45(2) Sydney Law Review 219
Sources: en.wikipedia.org
cloning The process of producing, either naturally or artificially, individual organisms or cells which are genetically identical to each other. Clones are the result of all forms of asexual reproduction, and cells that undergo mitosis produce daughter cells that are clones of the parent cell and of each other. Cloning may also refer to biotechnology methods which artificially create copies of organisms or cells, or, in molecular cloning, copies of DNA fragments or other molecules.
Like many other antifungals and antibiotics, nystatin has bacterial origin. It was isolated from Streptomyces noursei in 1950 by Elizabeth Lee Hazen and Rachel Fuller Brown, who were doing research for the Division of Laboratories and Research of the New York State Department of Health. Hazen found a promising micro-organism in the soil of a friend's dairy farm. She named it Streptomyces noursei, after Jessie Nourse, the wife of the farm's owner. Hazen and Brown named nystatin after the New York State Health Department in 1954. The two discoverers patented the drug, and then donated the $13 million in profits to a foundation to fund similar research.
A calcium gradient, with the lowest concentration in the stratum basale and increasing concentrations until the outer stratum granulosum, where it reaches its maximum. Calcium concentration in the stratum corneum is very high in part because those relatively dry cells are not able to dissolve the ions. Those elevations of extracellular calcium concentrations induces an increase in intracellular free calcium concentrations in keratinocytes. Part of that intracellular calcium increase comes from calcium released from intracellular stores and another part comes from transmembrane calcium influx, through both calcium-sensitive chloride channels and voltage-independent cation channels permeable to calcium. Moreover, it has been suggested that an extracellular calcium-sensing receptor (CaSR) also contributes to the rise in intracellular calcium concentration. Vitamin D3 (cholecalciferol) regulates keratinocyte proliferation and differentiation mostly by modulating calcium concentrations and regulating the expression of genes involved in keratinocyte differentiation. Keratinocytes are the only cells in the body with the entire vitamin D metabolic pathway from vitamin D production to catabolism and vitamin D receptor expression. Cathepsin E. TALE homeodomain transcription factors. Hydrocortisone. Since keratinocyte differentiation inhibits keratinocyte proliferation, factors that promote keratinocyte proliferation should be considered as preventing differentiation. These factors include:
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.